Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
about
The Under-Appreciated Promiscuity of the Epidermal Growth Factor Receptor FamilySafety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I studyExpression and clinical significance of fibroblast growth factor 1 in gastric adenocarcinoma.Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).Sprouty2 correlates with favorable prognosis of gastric adenocarcinoma via suppressing FGFR2-induced ERK phosphorylation and cancer progression.Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy.Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.A novel multikinase inhibitor R8 exhibits potent inhibition on cancer cells through both apoptosis and autophagic cell death.An FGFR inhibitor converts the tumor promoting effect of TGF-β by the induction of fibroblast-associated genes of hepatoma cells.Prognostic relevance of FGFR2 expression in stage II/III gastric cancer with curative resection and S-1 chemotherapy.The integration of genomics testing and functional proteomics in the era of personalized medicine.A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer.FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.
P2860
Q28073335-65BFA929-C571-4FD4-8DBF-25A7456708F4Q33885479-E98F4B2D-227F-42CA-AA64-7E6C8A0F110CQ35179821-3C582218-D04F-4DA4-9934-60447ED35B26Q36307708-10D0E65B-7A81-47A3-85D5-C602B3EB453DQ36436763-2FFAC412-4420-4563-B269-E51886433F5FQ36983860-30360290-3DA6-407F-BE3F-F3D313F6145BQ37706271-0614F5C8-87B8-44D5-B54E-1F54A948ECD4Q38527414-A2B9132E-1AEF-467F-8984-61AABB8856E4Q38713930-B4F7D955-52DE-45CB-B516-8FEB89A2B8ABQ44869860-0556190C-37F0-4E5E-AB6E-D94B44547D30Q47953832-E5CDE285-7611-4929-8C54-B8629532083EQ49639370-9F7907ED-E6AF-4FA8-99D4-C0F151FE6F1AQ50078274-FECE02D2-58AF-4606-80EE-B51728E034CFQ52766440-B608B4AA-53D4-4282-A9AC-53ECB1AE8F09Q55478389-A33FA6B5-2822-42B5-B174-BA75D40AE0A2
P2860
Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Multiple receptor tyrosine kin ...... GFR2 amplified gastric cancer.
@ast
Multiple receptor tyrosine kin ...... GFR2 amplified gastric cancer.
@en
type
label
Multiple receptor tyrosine kin ...... GFR2 amplified gastric cancer.
@ast
Multiple receptor tyrosine kin ...... GFR2 amplified gastric cancer.
@en
prefLabel
Multiple receptor tyrosine kin ...... GFR2 amplified gastric cancer.
@ast
Multiple receptor tyrosine kin ...... GFR2 amplified gastric cancer.
@en
P2093
P2860
P356
P1433
P1476
Multiple receptor tyrosine kin ...... GFR2 amplified gastric cancer.
@en
P2093
Congqi Dai
Jinjia Chang
Qunling Zhang
Ruixuan Geng
Rujiao Liu
Shanshan Wang
Xiaoxiao Ge
Xinyang Liu
P2860
P304
P356
10.18632/ONCOTARGET.2987
P407
P577
2015-02-01T00:00:00Z